BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 25605515)

  • 1. Intraoperatively assessed macroscopic serosal changes in patients with curatively resected advanced gastric cancer: clinical implications for prognosis and peritoneal recurrence.
    Yoo C; Ryu MH; Park YS; Yoo MW; Park SR; Ryoo BY; Jang SJ; Yook JH; Kim BS; Kang YK
    Ann Surg Oncol; 2015 Sep; 22(9):2940-7. PubMed ID: 25605515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnitude of serosal changes predicts peritoneal recurrence of gastric cancer.
    Bando E; Kawamura T; Kinoshita K; Takahashi S; Maeda A; Osada S; Tsubosa Y; Yamaguchi S; Uesaka K; Yonemura Y
    J Am Coll Surg; 2003 Aug; 197(2):212-22. PubMed ID: 12892799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proposal of a risk score for recurrence in patients with curatively resected gastric cancer.
    Ichikura T; Fujino K; Ikawa H; Tomimatsu S; Uefuji K; Tamakuma S
    Surg Today; 1993; 23(9):759-64. PubMed ID: 8219607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macroscopic serosal classification predicts peritoneal recurrence for patients with gastric cancer underwent potentially curative surgery.
    Sun Z; Xu YY; Wang ZN; Zhu Z; Zhang H; Huang BJ; Xu Y; Chen JQ; Xu HM
    Ann Surg Oncol; 2011 Apr; 18(4):1068-80. PubMed ID: 21293933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extent of Serosal Changes Predicts Peritoneal Recurrence and Poor Prognosis After Curative Surgery for Gastric Cancer.
    Kang Y; Li S; Ge Q; Liu X; Yang Z; Xue Y; Wang F
    Medicine (Baltimore); 2015 Oct; 94(42):e1750. PubMed ID: 26496292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical outcomes for gastric cancer patients with intraperitoneal free cancer cell, but no macroscopic peritoneal metastasis.
    Saito H; Kihara K; Kuroda H; Matsunaga T; Tatebe S; Ikeguchi M
    J Surg Oncol; 2011 Oct; 104(5):534-7. PubMed ID: 21618248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it time to abandon the 5-cm margin rule during resection of distal gastric adenocarcinoma? A multi-institution study of the U.S. Gastric Cancer Collaborative.
    Squires MH; Kooby DA; Poultsides GA; Pawlik TM; Weber SM; Schmidt CR; Votanopoulos KI; Fields RC; Ejaz A; Acher AW; Worhunsky DJ; Saunders N; Levine EA; Jin LX; Cho CS; Bloomston M; Winslow ER; Russell MC; Cardona K; Staley CA; Maithel SK
    Ann Surg Oncol; 2015 Apr; 22(4):1243-51. PubMed ID: 25316491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation.
    Piessen G; Messager M; Leteurtre E; Jean-Pierre T; Mariette C
    Ann Surg; 2009 Dec; 250(6):878-87. PubMed ID: 19855261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
    Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
    Ann Surg Oncol; 2012 May; 19(5):1568-74. PubMed ID: 22143578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Borrmann's macroscopic criteria and p-Smad2 expression are useful predictive prognostic markers for cytology-positive gastric cancer patients without overt peritoneal metastasis.
    Noda S; Yashiro M; Toyokawa T; Morimoto J; Shinto O; Muguruma K; Sawada T; Hirakawa K
    Ann Surg Oncol; 2011 Dec; 18(13):3718-25. PubMed ID: 21573834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
    Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Okada K; Mori M; Doki Y
    Ann Surg Oncol; 2011 Dec; 18(13):3726-31. PubMed ID: 21584835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Impact of Histologic Type in Curatively Resected Stage IV Colorectal Cancer: A Japanese Multicenter Retrospective Study.
    Shibata J; Kawai K; Nishikawa T; Tanaka T; Tanaka J; Kiyomatsu T; Hata K; Nozawa H; Kazama S; Yamaguchi H; Ishihara S; Sunami E; Kitayama J; Sugihara K; Watanabe T
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S621-9. PubMed ID: 26350364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.
    Stiekema J; Trip AK; Jansen EP; Boot H; Cats A; Ponz OB; Verheij M; van Sandick JW
    Ann Surg Oncol; 2014 Apr; 21(4):1107-14. PubMed ID: 24306660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Value of Signet-Ring Cell Histology in Resected Gastric Adenocarcinoma.
    Postlewait LM; Squires MH; Kooby DA; Poultsides GA; Weber SM; Bloomston M; Fields RC; Pawlik TM; Votanopoulos KI; Schmidt CR; Ejaz A; Acher AW; Worhunsky DJ; Saunders N; Swords D; Jin LX; Cho CS; Winslow ER; Cardona K; Staley CA; Maithel SK
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S832-9. PubMed ID: 26156656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenocarcinoma in the middle third of the stomach--an evaluation for the prognostic significance of clinicopathological features.
    Sheen-Chen SM; Chou CW; Chen MC; Chen FC; Chen YS; Chen JJ
    Hepatogastroenterology; 1997; 44(17):1488-94. PubMed ID: 9356878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. REGIV as a potential biomarker for peritoneal dissemination in gastric adenocarcinoma.
    Moon JH; Fujiwara Y; Nakamura Y; Okada K; Hanada H; Sakakura C; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
    J Surg Oncol; 2012 Feb; 105(2):189-94. PubMed ID: 21780125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palliative resection for advanced gastric and junctional adenocarcinoma: which patients will benefit from surgery?
    Mariette C; Bruyère E; Messager M; Pichot-Delahaye V; Paye F; Dumont F; Brachet D; Piessen G;
    Ann Surg Oncol; 2013 Apr; 20(4):1240-9. PubMed ID: 23064779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer patients with serosal invasion. A long-term follow-up study.
    Zhu ZG; Tang R; Yan M; Chen J; Yang QM; Li C; Yao XX; Zhang J; Yin HR; Lin YZ
    Dig Surg; 2006; 23(1-2):93-102. PubMed ID: 16763374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a risk-scoring system to evaluate the serosal invasion for macroscopic serosal invasion positive gastric cancer patients.
    Wang PL; Huang JY; Zhu Z; Gong BC; Huang HW; Duan SJ; Xu HM; Liu FN
    Eur J Surg Oncol; 2018 May; 44(5):600-606. PubMed ID: 29454557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
    Moon YW; Jeung HC; Rha SY; Yoo NC; Roh JK; Noh SH; Kim BS; Chung HC
    Ann Surg Oncol; 2007 Oct; 14(10):2730-7. PubMed ID: 17632757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.